1. Market Research
  2. > Malignant Pleural Effusion - Pipeline Review, H1 2013

Malignant Pleural Effusion - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 33 pages

Malignant Pleural Effusion - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Malignant Pleural Effusion - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Malignant Pleural Effusion, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Pleural Effusion. Malignant Pleural Effusion - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Malignant Pleural Effusion.
- A review of the Malignant Pleural Effusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Malignant Pleural Effusion pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Effusion.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Malignant Pleural Effusion pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Malignant Pleural Effusion - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Malignant Pleural Effusion Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Malignant Pleural Effusion 7
Malignant Pleural Effusion Therapeutics under Development by Companies 9
Malignant Pleural Effusion Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Malignant Pleural Effusion Therapeutics - Products under Development by Companies 13
Malignant Pleural Effusion Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Malignant Pleural Effusion Therapeutics Development 15
Biogen Idec Inc. 15
Nobelpharma Co., Ltd. 16
Genelux Corporation 17
Malignant Pleural Effusion - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
BG-00001 - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
GL-ONC-1 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
interferon alfa-2b - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
NPC-05 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Malignant Pleural Effusion Therapeutics - Drug Profile Updates 28
Malignant Pleural Effusion Therapeutics - Dormant Products 29
Malignant Pleural Effusion - Product Development Milestones 30
Featured News and Press Releases 30
May 30, 2013: Genelux To Present Abstracts For Clinical Trials Of Oncolytic Viral Therapy GL-ONC1 At 2013 ASCO Annual Meeting 30
Feb 06, 2013: Genelux Announces Treatment Of First Patient In Phase I Trial With GL-ONC1 At Memorial Sloan Kettering Cancer Center 30
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables


Number of Products Under Development for Malignant Pleural Effusion, H1 2013 7
Products under Development for Malignant Pleural Effusion - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 14
Biogen Idec Inc., H1 2013 15
Nobelpharma Co., Ltd., H1 2013 16
Genelux Corporation, H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
Malignant Pleural Effusion Therapeutics - Drug Profile Updates 28
Malignant Pleural Effusion Therapeutics - Dormant Products 29

List of Figures


Number of Products under Development for Malignant Pleural Effusion, H1 2013 7
Products under Development for Malignant Pleural Effusion - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.